315 related articles for article (PubMed ID: 34140003)
1. AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia.
Fatima M; Kakar SJ; Adnan F; Khan K; Mian AA; Khan D
BMC Cancer; 2021 Jun; 21(1):713. PubMed ID: 34140003
[TBL] [Abstract][Full Text] [Related]
2. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
[TBL] [Abstract][Full Text] [Related]
3. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
4. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
5. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
6. Blockade of deubiquitinase YOD1 degrades oncogenic PML/RAR
Shao X; Chen Y; Wang W; Du W; Zhang X; Cai M; Bing S; Cao J; Xu X; Yang B; He Q; Ying M
Acta Pharm Sin B; 2022 Apr; 12(4):1856-1870. PubMed ID: 35847510
[TBL] [Abstract][Full Text] [Related]
7. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
8. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
[TBL] [Abstract][Full Text] [Related]
9. Targeting expression of the leukemogenic PML-RARα fusion protein by lentiviral vector-mediated small interfering RNA results in leukemic cell differentiation and apoptosis.
Ward SV; Sternsdorf T; Woods NB
Hum Gene Ther; 2011 Dec; 22(12):1593-8. PubMed ID: 21846246
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
[TBL] [Abstract][Full Text] [Related]
11. Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance.
Hussain L; Maimaitiyiming Y; Islam K; Naranmandura H
Semin Oncol; 2019 Apr; 46(2):133-144. PubMed ID: 31126665
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
13. Targeting of leukemia-initiating cells in acute promyelocytic leukemia.
Testa U; Lo-Coco F
Stem Cell Investig; 2015; 2():8. PubMed ID: 27358876
[TBL] [Abstract][Full Text] [Related]
14. Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
Wu D; Shao K; Zhou Q; Sun J; Wang Z; Yan F; Liu T; Wu X; Ye B; Huang H; Zhou Y
Cell Physiol Biochem; 2018; 48(6):2286-2301. PubMed ID: 30114705
[TBL] [Abstract][Full Text] [Related]
15. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
16. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A
Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967
[TBL] [Abstract][Full Text] [Related]
17. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
18. Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.
Yang XW; Wang P; Liu JQ; Zhang H; Xi WD; Jia XH; Wang KK
Oncogene; 2014 May; 33(21):2700-8. PubMed ID: 23770850
[TBL] [Abstract][Full Text] [Related]
19. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
20. S100A3 a partner protein regulating the stability/activity of RARα and PML-RARα in cellular models of breast/lung cancer and acute myeloid leukemia.
Gianni M; Terao M; Kurosaki M; Paroni G; Brunelli L; Pastorelli R; Zanetti A; Lupi M; Acquavita A; Bolis M; Fratelli M; Rochette-Egly C; Garattini E
Oncogene; 2019 Apr; 38(14):2482-2500. PubMed ID: 30532072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
